Alliances and Partnerships, Business, Education and Schools, Free News Articles, Sciences

BioBuilder and K2 Scientific Bring Synthetic Biology Programs and Laboratory Equipment to High-Need High Schools Around the Country

BOSTON, Mass. -- As a world-recognized program that trains the next generation of innovators and skilled workers in synthetic biology, the BioBuilder Educational Foundation announced new work with K2 Scientific to make high quality tools and equipment for life science research widely accessible. BioBuilder has partnered with K2 Scientific, who will donate industry-grade refrigeration units to four high-need high schools participating in the BioBuilderClub this academic year.

Consistent refrigeration of laboratory reagents is essential for a wide variety of biotechnology experiments and applications. Without precise temperature control and storage, materials and supplies for life science research degrade. Yet many high school educators, especially those in under-resourced school districts, rely on limited and unreliable cold-storage units. Many teachers forgo hands-on laboratory experiments without the appropriate cold storage equipment.

Recognizing that many high schools face financial constraints that limit classroom opportunities in the field of synthetic biology, BioBuilder annually runs the BioBuilderClub program. Since its inception in 2015, more than 1850 students from demographically and geographically diverse schools in 24 states and 7 countries have participated in a total of 202 BioBuilderClubs at low or no cost to the schools themselves. The BioBuilderClub supports real and meaningful student research, enabling high school students to take their ideas from concept to prototype to publication.

On November 9, 2022, staff and leadership from K2 Scientific and BioBuilder identified the first of four BioBuilderClubs to receive a freezer this academic year. The first recipient is the BioBuilderClub team from the Manhattan Comprehensive Night and Day High School (MCNDHS), a public school in New York City that serves students in grades 10-12.

Alfred Lwin, the MCNDHS BioBuilderClub lead teacher, said, "Our refrigerator is 20 years old, and sometimes we have difficulties using its freezer for cold storage. Thanks to the generous donation of a lab grade refrigerator by K2 Scientific, we will be able to use cold storage for our BioBuilder and other biotechnology labs."

Dee Jetton, COO from K2 Scientific, shared, "We could not be prouder to support this program. I am always so excited to see the great things the BioBuilder Program and its participants are accomplishing. We are thrilled to contribute to BioBuilder programs around the country. K2 Scientific is committed to equity and inclusion, so bringing medical and laboratory grade equipment to high-need schools is a perfect mission fit. It's nice for our team to learn about students' aha moments and accomplishments resulting from K2's support of young scientists in the field."

Founder and Executive Director of BioBuilder, Dr. Natalie Kuldell noted, "Our BioBuilderClubs are often the first - and sometimes the only - time high school students can engage in authentic research before they launch into college or careers. By making that research experience more accessible and more meaningful, we can effectively engage the next generation of scientific innovators and productively prepare our future citizens."

About BioBuilder:

Created by an award-winning team from MIT, BioBuilder empowers teachers and schools to better serve students and employers by elevating the skills that students are taught. Founded in 2011, BioBuilder has grown to partner with schools in almost every state and around the world. BioBuilder builds confidence in teachers to learn and apply the synthetic biology curricula, and provides laboratory kits and an openly accessible textbook that enable experiential learning.

BioBuilder also works directly with district and community leaders to identify potential roadblocks to narrow the gap between science innovation and science education - at least for biology - across the U.S., and better match the skill of our nation's workforce to the needs of the synthetic biology industry. Learn more by visiting https://biobuilder.org/.

About K2 Scientific:

K2 Scientific provides high-performance, medical, cold storage solutions at value prices, offering an extensive line serving US Life Science corporations and North and South American distributors. All K2 orders ship from the North Carolina basecamp. For more information, visit https://k2sci.com and follow us on LinkedIn, Instagram @K2_Scientific

Related link: https://biobuilder.org/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Alliances and Partnerships, Business, Free News Articles, Software

Dosaggio™ by SottoPelle® Partners with PatientNow

SCOTTSDALE, Ariz. -- Dosaggio™ by SottoPelle® and PatientNow announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).

This collaboration offers medical providers a powerful and seamless integration of capabilities for bioidentical hormone replacement therapy practices.

This partnership brings together PatientNow's robust functional EHR with the advanced and powerful Dosaggio™ hormone dosing tool, enabling medical providers to expand their functional medicine practices into the bioidentical hormone therapy arena.

PatientNow is a functional, full-service EHR that offers customized and integrated scheduling, charting, billing, reporting, prescription management, and treatment plan solutions for medical practices. The PatientNow EHR offers flexibility for each provider's needs - all with fair pricing.

The Dosaggio™ bioidentical hormone pellet therapy dosing application allows medical providers to optimize their patient's hormone health through precise, individualized hormone dosing. Dosaggio™ by SottoPelle® offers providers a proprietary online hormone dosing calculator that uses the patient's unique health data to calculate a precise, individualized BHRT dose. Dosaggio™ combines a powerful algorithm with on-screen clinical guidance that enables medical providers to approach each patient's hormone health care in an individualized manner.

The integration of these two platforms allows medical providers to pull patient data such as lab work, demographics, past hormone therapy notes, and other documentation from their PatientNow EHR into the Dosaggio™ dosing application. This eliminates the need for double documentation and helps seamlessly maintain continuity of care for BHRT patients.

"The Dosaggio and PatientNow integration will help providers bring quality care to their patients who suffer from hormonal imbalance," stated CarolAnn Tutera, CEO of Dosaggio™ by SottoPelle®. "It is our mission to help providers bring individualized care to more patients, to help them age gracefully."

Practices that are currently using PatientNow's EHR can conveniently set up their Dosaggio™ account by visiting the integrations page within their account. Medical providers who are interested in learning more about this exciting integration may visit: https://sottopelle.health.

Related link: https://www.sottopelletherapy.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Alliances and Partnerships, Business, Free News Articles

Dosaggio by SottoPelle Partners with Cerbo

SCOTTSDALE, Ariz. -- Dosaggio™ by SottoPelle® and Cerbo announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).

Dosaggio™, the original, multi-patented hormone therapy dosing platform for physicians, announces its exciting new partnership with Cerbo electronic health records (EMR). This collaboration offers medical providers a powerful and seamless integration of capabilities for bioidentical hormone replacement therapy practices.

This partnership brings together Cerbo's robust functional EHR with the advanced and powerful Dosaggio™ hormone dosing tool, enabling medical providers to expand their functional medicine practices into the bioidentical hormone therapy arena.

Cerbo is a functional, full-service EHR that offers customized and integrated scheduling, charting, billing, reporting, prescription management, and treatment plan solutions for medical practices. The Cerbo EHR offers flexibility for each provider's needs - all with fair pricing.

The Dosaggio™ bioidentical hormone pellet therapy dosing application allows medical providers to optimize their patient's hormone health through precise, individualized hormone dosing. Dosaggio™ by SottoPelle® offers providers a proprietary online hormone dosing calculator that uses the patient's unique health data to calculate a precise, individualized BHRT dose. Dosaggio™ combines a powerful algorithm with on-screen clinical guidance that enables medical providers to approach each patient's hormone health care in an individualized manner.

The integration of these two platforms allows medical providers to pull patient data such as lab work, demographics, past hormone therapy notes, and other documentation from their Cerbo EHR into the Dosaggio™ dosing application. This eliminates the need for double documentation and helps seamlessly maintain continuity of care for BHRT patients.

"The Dosaggio and Cerbo integration will help providers bring quality care to their patients who suffer from hormonal imbalance," stated CarolAnn Tutera, CEO of Dosaggio™ by SottoPelle®. "It is our mission to help providers bring individualized care to more patients, to help them age gracefully."

Practices that are currently using Cerbo's EHR can conveniently set up their Dosaggio™ account by visiting the integrations page within their account.

Medical providers who are interested in learning more about this exciting integration may visit: https://sottopelle.health.

Learn more about SottoPelle® Therapy at: https://www.sottopelletherapy.com/.

Related link: https://www.sottopelletherapy.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Education and Schools, Free News Articles, Funding and Investment

BioBuilder funded to expand student opportunity in rural and urban areas through its collaborative after school program

BOSTON, Mass. -- Thanks to a two-year grant recently awarded by BioMADE, the BioBuilder Educational Foundation will expand a program that has supported thousands of high school inventors over the last decade. BioBuilder is leading the project, "Launching High School Bioengineers on their Paths to College and Careers," with funding that will bring the authentic tools and approaches for engineering biology to BioBuilderClub students nationwide in collaboration with East Tennessee State University, Ars Biotechnica, and Daicel Arbor Biosciences.

Support from BioMADE will enable these organizations to provide teams of young innovators new opportunities to design, build and test their biodesigns, and submit their research for publication as peer-reviewed manuscripts in BioTreks (Ars Biotechnica). Industry-standard biomanufacturing reagents and mentorship from professional scientists will be provided by Daicel Arbor, while East Tennessee State University will expand the geographic and demographic reach of the BioBuilderClub and spearhead a rigorous evaluation of its impact.

Thomas Tubon, Chief Workforce Development Officer for BioMADE said, "With the bioeconomy expected to contribute over a million jobs in this field by 2030, and the growing desire to connect local feedstocks to nearby manufacturing capabilities, a program like this is essential as it can raise awareness and provide opportunities to students, regardless of geography or demography."

Founder and Executive Director of BioBuilder, Dr. Natalie Kuldell shared that, "We are thrilled to be building momentum in non-traditional STEM hubs. By simultaneously training students and celebrating their achievements, this work will draw students into the exciting and creative sides of science and engineering. It will also increase awareness among community stakeholders, including parents of participating students, high school teachers, college admissions officers, and relevant local businesses."

These goals are fully aligned with the recently signed Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy that establishes the National Biotechnology and Biomanufacturing Initiative. The National Biotechnology and Biomanufacturing Initiative will create jobs, leverage biotechnology to build more resilient supply chains, improve health outcomes, and lower prices for Americans by expanding biomanufacturing capacity, creating market pathways for bio-based products, training a diverse workforce, and fostering innovation.

About BioBuilder:

Created by an award-winning team from MIT, BioBuilder empowers teachers and schools to better serve students and employers by elevating the skills that students are taught. Founded in 2011, BioBuilder has grown to partner with schools in almost every state and around the world. BioBuilder builds confidence in teachers to learn and apply the synthetic biology curricula, and provides laboratory kits and an openly accessible textbook that enable experiential learning.

BioBuilder also works directly with district and community leaders to identify potential roadblocks to narrow the gap between science innovation and science education -- at least for biology - across the U.S., and better match the skill of our nation's workforce to the needs of the synthetic biology industry. Learn more by visiting https://biobuilder.org/.

About BioMADE:

Launched in 2021, BioMADE is a Manufacturing Innovation Institute sponsored by the U.S. Department of Defense. By supporting the development of biomanufacturing technologies, BioMADE and its network of 150+ members across 29 states are strengthening American competitiveness, creating a more resilient supply chain, and helping the U.S. becoming more self-sufficient. Learn more about BioMADE by visiting https://www.biomade.org/.

About ETSU:

East Tennessee State University (ETSU) is a public research university in Johnson City, Tennessee. It is the fourth largest university in the state with nearby off-campus centers. It hosts the James H. Quillen College of Medicine, often ranked as one of the top schools in the United States for rural medicine and primary care education; the Bill Gatton College of Pharmacy, the College of Nursing, the College of Public Health, and the recently formed College of Clinical and Rehabilitative Health Sciences. Learn more about ETSU at https://www.etsu.edu/.

About Ars Biotechnica:

Ars Biotechnica is a public nonprofit corporation with the goal of teaching high school students and teachers about synthetic biology. They publish BioTreks, the first international synthetic biology journal to be authored and reviewed by high school students. The journal is intended to give participating students the valuable experiences of writing and evaluating scientific papers, while offering them opportunities to share their own synthetic biology ideas, techniques, and results in a professionally edited, online publication. Learn more by visiting https://biotreks.org/.

About Daicel Arbor Biosciences:

Daicel Arbor Biosciences, a subsidiary of Chiral Technologies, Inc. (part of Daicel Corporation), is a biotech company that is specialized in targeted Next Generation Sequencing (NGS), in situ hybridization probe design, and cell-free protein expression. Their products and services have been utilized in broad applications in genomics, cytogenetics, and synthetic biology. They have served customers in plant, animal, human, bacteria, and virus areas for more than fifteen years. Learn more by visiting https://arborbiosci.com/.

Related link: https://biobuilder.org/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Drugs and Pharmaceuticals, Free News Articles

Kalyagen Announces Attendance and Speaking Engagement at 8th Annual Biohacking Conference

AUSTIN, Texas -- Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.

"The Biohacking Conference will be an ideal opportunity to introduce STEMREGEN directly to an audience whose core focus is to tap into the body's innate ability to repair," said Christian Drapeau. "We are eager to meet and collaborate with the leaders of the biohacking movement."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in anti-aging and overall health maintenance.

"The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," continued Mr. Drapeau. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in many degenerative conditions and overall health and well-being."

About Kalyagen:

Austin-based Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our website: https://www.kalyagen.com/

CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

Social media: @kalyagen #kalyagen #christiandrapeau #stemcellchristian #stemregen #stemcells #stemregeneffect #stemthetideoftime #stemthetide #biohacking

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Related link: https://www.kalyagen.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Funding and Investment

Proteios Technology, Inc. Awarded $1.6 Million NIH SBIR Grant to Commercialize its Multivariate Cell Isolation Technology

SEATTLE, Wash. -- Proteios Technology, Inc. is pleased to announce it's received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios' cell isolation kits to include up to 20 of the most common cell types currently used in cell therapy development.

Cell biology is complex. And conducting experiments on an isolated population of cells, rather than a heterogeneous mix, is a common approach to reduce experimental complexity. Cell isolation allows cell biologists to confidently attribute observed effects and responses to a particular cell type.

Specifically, Proteios' multivariate cell isolation technology provides high-performance, antibody- and magnetic bead-free isolation of cell types in fewer than 30 minutes. This is a big reduction in time compared to currently available methods, while meeting or exceeding cell yield, purity and viability.

Proprietary Proteios Chimeras will be designed and developed to bind to each of the 20 target cell types with high specificity and selectivity through a combination of robotic biological screening, Machine Learning (ML) and Molecular Dynamics (MD) simulation.

Proteios will also incorporate Proteios Chimeras into its cGMP cell therapy manufacturing device - a bench prototype funded under contract by the National Cancer Institute (NCI). The device provides end-to-end manufacturing of cell therapies in a closed and fully-automated system with concise control over the multiple cell types that form the basis of cell therapy formulations. Proteios Chimeras will be a major component of consumables for the cGMP cell therapy manufacturing device.

"It's believed that the effectiveness of cellular therapeutics can be improved by the addition/removal of certain secondary cell types," Bob Snyder, Ph.D., co-founder and CEO of Proteios Technology, says. "Proteios' cell isolation technology will provide for the parallel enrichment and/or depletion of any cell type as new cell therapy formulations are investigated, reducing the vein-to-vein time and overall manufacturing cost."

Proteios is also preparing for the immediate commercial release of its research-scale recombinant protein purification kits which will provide a viable alternative to His Tag technology, unusable with about 20 percent of proteins of interest.

Initially, Proteios will launch two kits based on a proprietary affinity tag and a silica-based resin for:

1 - high-expressing proteins; and

2 - low-expressing proteins.

To learn more: https://www.proteios.com/

About Proteios Technology:

Proteios Technology is a leading provider of products and services dedicated to supporting the discovery of advanced therapeutics and their efficient manufacturing. Its innovative solutions support research at all levels from discovery and translational research to cGMP manufacturing and companion diagnostics. Its technologies enable the multivariate (parallel), tag-free isolation of any biological, including proteins/biopharmaceuticals, cell types, antibodies and viruses. Proteios' research-scale kits enable the discovery of new advanced therapeutics. And the inherent scalability of the technology allows the same methodology to be used in the manufacturing of advanced therapeutics and dramatically reduces the time required for process development.

Proteios is driven by the goal to lower the cost of healthcare and to provide advanced therapeutics to a larger patient population. It's located in the heart of Seattle and adjacent to some of the world's leading cell therapy research institutes - including the Fred Hutchinson Cancer Research Center, Seattle Children's Research Institute and the Seattle Cancer Care Alliance.

Related link: https://www.proteios.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles

Kalyagen Announces Attendance at the Fort Lauderdale Open with PGA Associate Jerrel Gill

AUSTIN, Texas -- Kalyagen® is pleased to announce that it will be attending the Fort Lauderdale Open as part of its sponsorship of golf professional Jerrel Gill. The Open will be hosted at the Fort Lauderdale Country Club on May 2-3, 2022. Kalyagen is also a supporting partner for two upcoming South Florida PGA Section events, the South Florida PGA Foundation HOPE Classic on May 12, 2022 and the South Florida Open on June 21-23, 2022.

"I'm pleased to introduce Kalyagen to the Fort Lauderdale Open and the South Florida PGA and the PGA Hope program benefiting veterans like myself and some of my team members," said Desmond Dogan, Director of Sales at Kalyagen®. "As a former golf professional and club pro, I understand the grind that is associated with practicing, playing, teaching, running the pro shop and more. That's why I'm pleased that Kalyagen is sponsoring Jerrel Gill, presently a Class B-13 PGA Associate. Jerrel will be playing in both the Fort Lauderdale Open and the Hope Classic and will attempt to qualify for the South Florida Open."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

"Despite my local success, I am determined to improve my game and consistently compete against the best PGA Professionals," said Jerrel Gil, PGA professional golfer. "I have been fortunate enough to partner with Kalyagen and use its stem cell enhancement supplement STEMREGEN to assist me to contend in the South Florida PGA Section and hopefully on the PGA Tour. I've already picked up distance on my drive!"

"We are delighted to partner with Jerrel and the South Florida PGA Section," said Kalyagen® founder and CEO Christian Drapeau. "The link between a lower number of circulating stem cells and the development of age-related diseases and lack of recovery has been well studied. From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair and improve the course of disease formation in many degenerative conditions and overall health and well-being. We have already begun to see improvement in Jerrel's training and recovery efforts and look forward to continuing to assist his golf career with the benefits of STEMREGEN on his team."

About Kalyagen:

Austin-based Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits. For more information, please visit our Website: https://www.kalyagen.com/.

About Jerrel Gill:

Jerrel Gill has excelled in various management fields since graduating with honors from Hampton University with a Bachelor's of Science in Business Management. Hampton University is a historic Black college and university in Hampton, Virginia. Mr. Gill reentered the golf industry as a registered PGA Associate in April of 2019 and was quickly promoted to Assistant Golf Professional at Plantation Preserve Golf Course and Club in Plantation, Florida. In March 2020, he was promoted to General Manager of The Bridges at Springtree Golf Club in Sunrise, FL. During the last three years as a PGA Associate, Mr. Gill has quickly made himself known as a competitive golfer in the South Florida PGA Section. His best finish was a tie for 2nd place at the 2021 DEK Classic with an additional five top-15 finishes in the Southern Section in 2021.

About Desmond Dogan:

Following high school and a once-in-a lifetime experience with the USA Jr. National Olympic Hockey Team, Mr. Dogan served as a Navy Corpsman. After a successful five-year stint with the Navy, Mr. Dogan spent the next twelve years as an Operating Room Technician at LA-based Cedar Sinai Medical Center. After graduating from the Orlando Chapter of the Golf Academy of America and passing the PGA playing ability test on his first attempt, Mr. Dogan was offered the Head Professional position at the famed Inverrary Country Club. This led to a Head Professional/ Director of Golf position with the Billy Casper Golf Management group in Chicago. In addition to his current role with Kalyagen®, Mr. Dogan continues to be heavily involved in the not-for-profit world.

CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

SOCIAL MEDIA:

@kalyagen @southfloridapga #kalyagen #stemregen #stemcells #stemregeneffect #stemthetideoftime #stemthetide #pga #southfloridapga #jerrelgill #fortlauderdaleopen

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Related link: https://www.kalyagen.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles

Kalyagen Announces Attendance at Paleo f(x) 2022 Conference

AUSTIN, Texas -- Kalyagen is pleased to announce that it will be attending and hosting a booth (#121) at the upcoming Paleo f(x)™ 2022 conference to be held in Austin on April 29 - May 1.

"We recently attended the SXSW Conference and received a warm welcome from the Austin community," said Christian Drapeau, Kalyagen founder. "Paleo f(x) will be another opportunity to present STEMREGEN to our home-town Austin community at one of the world's premier wellness events."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

"The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," continued Mr. Drapeau. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in many degenerative conditions and overall health and well-being."

ABOUT KALYAGEN:

Austin-based Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our Website: https://www.kalyagen.com/

CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

SOCIAL MEDIA:

@kalyagen #kalyagen #stemregen #stemcells #stemregeneffect #stemthetideoftime #stemthetide #paleofx #wellnessexpo #austin

DISCLAIMER:

None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Related link: https://www.kalyagen.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine

ROCHESTER, Minn. -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine accessible at http: https://www.sciencedirect.com/science/article/pii/S0264410X21016716

The article describes the evaluation of an oral COVID-19 vaccine built on the vesicular stomatitis virus (VSV) platform. Oral administration of the VSV based vaccine induced antibodies that could neutralize SARS-CoV-2, the virus that causes COVID-19. More importantly, the novel oral formulation powerfully boosted the levels of neutralizing antibodies against SARS-COV-2 in previously vaccinated monkeys. The oral vaccine was shown to be safe and did not cause clinically significant adverse effects.

"By tweaking the way we generate the VSV-SARS vaccine, we created a new oral formulation that worked remarkably well to boost virus neutralizing antibody titers when administered into the cheek pouches of cynomolgus macaques whose immunity was waning after they had been primed with an intramuscular vaccine," stated Kah-Whye Peng, Ph.D., Chief Technical Officer of Vyriad, and first author of this publication. "Oral dosing is convenient and more likely to be accepted by people who are reluctant to receive yet another intramuscular injection to boost their immunity."

The COVID-19 pandemic is not over and there is a continued need to deliver vaccines to a much of the world's population. An effective oral vaccine/booster has the potential to dramatically improve vaccine uptake rates by addressing some of the key barriers to effective deployment such as logistics of distribution to remote populations, fear of needles, and administration to young children.

"We are excited by these groundbreaking findings. Vyriad has cGMP manufacturing capabilities and is running clinical trials using an engineered VSV for cancer therapy. We are therefore actively seeking partnership to help bring this promising platform to human testing," stated Stephen J Russell, M.D., Ph.D., Chief Executive Officer of Vyriad.

The publication is a collaboration between researchers at Vyriad, Imanis Life Sciences, Regeneron Pharmaceuticals, and the University of Minnesota.

About Vyriad, Inc.

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad is working with VSV, measles and picornavirus platforms, programming their viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence.

Our lead platform, derived from vesicular stomatitis virus (VSV), is being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have a well-established broad-based strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab-rwic) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.

For more information, visit https://vyriad.com/.

Related link: https://vyriad.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles

Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies

OKLAHOMA CITY, Okla. -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

The cancer therapies resulting from this collaboration will represent a unique synergism: Myrio's ReD platform is differentiated in its ability to routinely identify antibodies that bind to peptides from intracellular proteins presented on the cell surface by major histocompatibility complex (MHC), and Pure MHC is a world-leader in the identification and validation of peptide/MHC (pMHC) targets. Antibodies to next generation pMHC oncology targets may provide more efficacious therapies, particularly for solid tumors, while minimizing off-target effects for patients.

Researchers at both companies expressed excitement at the prospect of combining these innovative approaches:

"The speed and flexibility of Myrio's ReD platform enables the generation of robust antibody-based therapies against challenging targets like pMHC with high affinity and specificity," said Myrio's CEO Pete Smith. "Pure MHC's curated pMHC targets are an excellent fit for our platform and substantially de-risk downstream development."

Pure MHC's Chief Scientist, William Hildebrand, PhD shared this enthusiasm, "Pure MHC is dedicated to the identification of pMHC complexes distinct to cancer and absent from healthy tissues. Peptide/MHC complexes for several oncology indications have been identified by Pure MHC as present on tumors yet absent from healthy tissue, and we are excited for Myrio to deploy their cutting-edge technology to engineer antibodies that recognize our targets with great specificity."

From a business perspective, these therapeutic candidates will bolster Myrio's existing portfolio of in-house assets while providing Pure MHC access to a powerful antibody platform that enables multiple therapeutic pipelines.

"Myrio's platform is not just an outstanding scientific fit, the collaboration represents a unique and exciting way for Pure MHC to deploy its novel target assets strategically," said Kris Looney, President of Pure MHC. "As we continue to provide targets from our pipeline to the market via more traditional partner licensing models, we felt the time was right to also establish our own therapeutic pipeline and have found exactly the collaborator we need in Myrio."

Pete Smith agreed, "With the close alignment of both scientific and business objectives between our two companies, a partnership between Myrio and Pure MHC just makes so much sense. We are excited about its potential."

The companies expect the collaboration to yield therapeutic candidates within the next twelve months.

About Myrio Therapeutics

Myrio Therapeutics is driving a new frontier of antibody-based therapies as the company's Retained Display(tm) (ReD) antibody platform offers identification of highly specific human antibodies that bind to peptide-MHC complexes. Myrio's antibodies can readily be converted into multispecific, CAR-T or other formats, dramatically increasing the target landscape for these modalities. Visit: http://www.myriotx.com/

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious disease, and autoimmune diseases. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Science Center. For more information, visit: https://puremhc.com/

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.etibio.com/

Related link: https://puremhc.com/

This news story was published by the Neotrope® News Network - all rights reserved.